FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and refers to a conjugate comprising at least one selectivity agent specifically binding to at least one neurotransmitter transporter and selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a noradrenaline reuptake inhibitor (NRI), a norepinephrine and dopamine reuptake inhibitor (NDRI), and a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI), and at least one nucleic acid adapted to specifically bind to a target molecule expressed in a cell in which the neurotransmitter transporter is expressed. Group of inventions also relates to the use of said conjugate in the treatment and / or prevention of a disorder associated with depression, in the treatment and / or prevention of a disease associated with the deposition of Lewy bodies.
EFFECT: group of inventions ensures the start of internalisation of the nucleic acids of the claimed conjugates in cells expressing the neurotransmitter transporters with which they interact.
18 cl, 42 dwg, 2 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
TREATING DISEASES ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BY SUPPRESSION OF NATURAL ANTISENSE VEGF TRANSCRIPT | 2009 |
|
RU2569182C2 |
TREATMENT OF OBESITY WITH ANTAGONISTS OF MUSCARINIC RECEPTOR M1 | 2007 |
|
RU2455981C2 |
LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | 2014 |
|
RU2649367C2 |
TREATING PSYCHOLOGICAL CONDITIONS WITH USING M-MUSCARINIC ANTAGONISTS | 2007 |
|
RU2477634C2 |
APPLICATION OF N-DISMETILKLOSAPINE FOR HUMAN NEUROPSYCHIATRIC DISEASES TREATMENT | 2004 |
|
RU2336879C2 |
COMPLEXES BASED ON MICRO-BUBBLES AND METHODS OF APPLICATION | 2012 |
|
RU2613321C2 |
TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) ASSOCIATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1 | 2011 |
|
RU2611195C2 |
COMPOSITION OF DELIVERY SYSTEM BASED ON CONJUGATE FOR RNA-INTERFERENCE POLYNUCLEOTIDE DELIVERY TO LIVER CELL AND PROCESS FOR ITS PREPARATION | 2011 |
|
RU2623160C9 |
NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN CELL | 2018 |
|
RU2822093C1 |
TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF | 2013 |
|
RU2661104C2 |
Authors
Dates
2018-08-17—Published
2011-04-19—Filed